Bromotetrandrine, formerly known as BrTet and W-198, is an P-glycoprotein inhibitor. P-gp inhibitors were developed and coadministered with chemotherapeutic drugs to overcome the effect of efflux pumps thus enhancing the chemosensitivity of therapeutics. The pharmacokinetics parameters of bromotetrandrine indicated that the compound was rapidly distributed and accumulated in the tissues, and slowly cleared from plasma, which supported the use of BrTet for a once or twice dosing per chemotherapy cycle. References: Zheng L, Qing YP, Xu N, Yu Q, Wang Y, Wang FP, Li ZY. Pharmacokinetics and safety of bromotetrandrine (BrTet, W198) after single-dose intravenous administration in healthy Chinese volunteers. J Clin Pharm Ther. 2010 Feb;35(1):113-9. doi: 10.1111/j.1365-2710.2009.01075.x. PubMed PMID: 20175820.

纯度：≥98%

CAS：62067-29-2